Diabetes

Novo Nordisk® logo

Diabetes

The Patient Assistance Program will continue to support patients with the greatest need. Medicare beneficiaries can still access Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg for Type 2 Diabetes through most plans. Novo Nordisk is committed to advancing solutions to support access and affordability for all patients within the U.S. health care system.

2026 Eligibility Criteria and Additional Information

What is changing in 2026 for the Novo Nordisk Patient Assistance Program (PAP)?

For patients on Ozempic®

  • Most Medicare Part D plans cover Ozempic®. Medicare beneficiaries with Part D coverage will no longer be eligible to receive Ozempic® through the Patient Assistance Program.
  • Next Steps:
    • Confirm your coverage: Evaluate your plan options before 2026 Open Enrollment, which begins on October 15, 2025 and ends on December 7, 2025.
    • Find available health plans: Information about available health plans can be found here starting October 1, 2025, as well as other information about enrollment and Medicare Part D.
    • Plan your spending: You also have the option of spreading your prescription costs throughout the plan year by enrolling in the Medicare Prescription Payment Plan (M3P). To learn more about this program, click here.
  • Uninsured patients will still have access to Ozempic® through the Patient Assistance Program; however, their total household income must be at or below 200% of the federal poverty level.
  • Next Steps:

For Medicare patients on Novo Nordisk insulins

  • Medicare beneficiaries with a total household income below 150% of the federal poverty level must provide proof of denial for Part D Extra Help (Low Income Subsidy) to qualify.
  • Next Steps:
    • For more information on how to apply for the Extra Help Program, please click here. If you will be a Medicare patient in 2026 and meet eligibility requirements, please download the application in English or Spanish to apply.
    • Novo Nordisk has other programs to help make insulin affordable. Explore your options.

For uninsured patients on all products

  • Uninsured patients must provide proof of a Medicaid denial prior to enrollment in the PAP if the patient’s total household income meets their state federal poverty limit thresholds. For more information about your state’s Medicaid program, you can click here. You can also visit the Needy Meds website which lists the current FPL guidelines for more information.
  • Next Steps:
The following products will be removed from the Patient Assistance Program in 2026 for all patients:
  • RYBELSUS® (semaglutide) tablets 7 mg or 14 mg
  • All unbranded biologic insulins
If you meet these eligibility requirements, you can apply for the Patient Assistance Program by downloading the application in English or Spanish